## IDEAYA Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023

SOUTH SAN FRANCISCO, Calif., Jan. 3, 2023 /<u>PRNewswire</u>/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 41st Annual J.P. Morgan Healthcare Conference.

J.P. Morgan 41st Annual Healthcare Conference

Tuesday, January 10, 2023 at 4:30 pm PT (7:30 pm ET)

 Presentation by Yujiro S. Hata, Chief Executive Officer followed by analyst-hosted Q&A with Anupam Rama, Managing Director, US SMID Biotechnology Equity Research, J.P. Morgan

A live audio webcast of the event will be available, as permitted by conference host, at the "Investors/ Events" section of the IDEAYA website at <u>https://ir.ideayabio.com/events</u>. A replay of the webcast will be accessible for 30 days following the live event.

## **About IDEAYA Biosciences**

IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.

## **Forward-Looking Statements**

This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Quarterly Report on Form 10-Q filed on November 8, 2022 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

Paul Stone Senior Vice President and Chief Financial Officer investor@ideayabio.com

SOURCE IDEAYA Biosciences, Inc.

https://ir.ideayabio.com/2023-01-03-IDEAYA-Biosciences-to-Present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference-on-Tuesday,-January-10,-2023